GLP-1 and Its Role in Glycogen Production: A Narrative Review

GLP-1 and Its Role in Glycogen Production: A Narrative Review

Glucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 diabetes mellitus (T2DM). GLP-1 receptor agonis...

Full description

Saved in:

Bibliographic Details
Main Authors:	Joseph Lotosky, Xavier Jean, Anungoo Altankhuyag, Saqib Khan, Ashley Bernotas, Alireza Sharafshah, Kenneth Blum, Alan Posner, Panayotis K. Thanos
Format:	Article
Language:	English
Published:	MDPI AG 2025-06-01
Series:	Biomedicines
Subjects:	glucagon-like peptide-1 (GLP-1) glucagon-like peptide-1 receptor (GLP-1R) glucagon-like peptide-1 receptor agonist (GLP-1RA) glycogen glycogenesis thermogenesis
Online Access:	https://www.mdpi.com/2227-9059/13/7/1610
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Decreased incidence of hidradenitis suppurativa and psoriasis in diabetic patients treated with GLP-1 receptor agonists: A retrospective cohort study
by: Lauren M. Ching, BS, et al.
Published: (2025-10-01)

The Neuroprotective Effects of GLP-1 Analogues on Alzheimer's Disease – A Literature Review
by: Wiktoria Ulicka, et al.
Published: (2025-04-01)

Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trialResearch in context
by: Mads Gamborg, et al.
Published: (2025-08-01)

Improving Reproductive Outcomes in PCOS: The Emerging Role of GLP-1 Receptor Agonists
by: Adrianna Tabeau, et al.
Published: (2025-03-01)

Glucagon-like peptide 1 receptor agonists and cancer risk: advancing precision medicine through mechanistic understanding and clinical evidence
by: Anqi Lin, et al.
Published: (2025-03-01)

Safety and efficacy of glucagon-like peptide-1 receptor agonists in patients with obstructive sleep apnea: a systematic review and meta-analysis of randomized controlled trials
by: Obieda Altobaishat, et al.
Published: (2025-12-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists therapy initiation in patients with type 2 diabetes hospitalized with coronavirus infection
by: T. N. Markova, et al.
Published: (2023-12-01)

Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

Short- and long-term glycemic effects of pasireotide in patients with acromegaly: a comprehensive case study with review of literature
by: Yuki Taki, et al.
Published: (2025-04-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Clarifying methodological approaches in the assessment of GLP-1 RAs and gastrointestinal cancer risk
by: Gisella Figlioli, et al.
Published: (2024-12-01)

What Are the Experiences, Views and Perceptions of Patients, Carers and Clinicians of Glucagon‐like Peptide‐1 Receptor Agonists (GLP‐1 RAs)? A Scoping Review
by: Sam Febrey, et al.
Published: (2025-04-01)

Addressing weight loss management in obese gout patients: guidance for future trials
by: Robin Christensen, et al.
Published: (2024-11-01)

Efficacy and Safety of Glucagon‐Like Peptide‐1 Agonists for Psychiatric Symptoms: A Systematic Review
by: Shakila Meshkat, et al.
Published: (2025-07-01)

Efficacy and safety of glucagon-like peptide-1 receptor agonists in the elderly versus non-elderly patients with type 2 diabetes mellitus: insights from a systematic review
by: Yao Wang, et al.
Published: (2024-06-01)

Glucagon and Glucose Availability Influence Metabolic Heterogeneity and Malignancy in Pancreatic Neuroendocrine Tumour (pNET) Cells: Novel Routes for Therapeutic Targeting
by: Bárbara Ferreira, et al.
Published: (2025-06-01)

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: historical development and future challenges
by: Francisco Westermeier, et al.
Published: (2025-01-01)

Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Semaglutide and the Retina
by: Zachary T. Bloomgarden
Published: (2025-04-01)

Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
by: Dariush Mozaffarian, et al.
Published: (2025-09-01)

Granuloma annulare after starting semaglutide
by: Tajena Jones, BS, et al.
Published: (2025-08-01)

Glucagon-like peptide-1 receptor agonists in liver transplant recipients with diabetes: changes in glucose control and cardiometabolic risk factors
by: Valeria Grancini, et al.
Published: (2025-05-01)

Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis
by: Mohammad Amin Karimi, et al.
Published: (2025-05-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Population profile and glycemic control following initiation or switch of injectable therapies in Tianjin, China: A real‐world retrospective cohort study of adults with type 2 diabetes
by: Qiumei Zhang, et al.
Published: (2025-05-01)

One step closer to solving the mystery of the anti‐inflammatory effects of glucagon‐like peptide‐1 receptor agonists
by: Hirotaka Watada
Published: (2025-02-01)

Obesity and heart failure with preserved ejection fraction: focus on new drugs and future direction in medical treatment
by: Se-Eun Kim, et al.
Published: (2025-05-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

Glucagon-like peptide-1 receptor agonists in neurodegenerative diseases: Promises and challenges
by: Zhi Dong Zhou, et al.
Published: (2025-06-01)

The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction
by: N. D. Kozhukhov, et al.
Published: (2020-04-01)

Promising areas of pharmacotherapy for obesity
by: M. A. Druzhilov, et al.
Published: (2021-04-01)

Characterization of treatment intensified (add‐on to metformin) adults with type 2 diabetes in Thailand: A cross‐sectional real‐world study (CONVERGE)
by: Chutintorn Sriphrapradang, et al.
Published: (2025-06-01)

The hidden impact of GLP‐1 receptor agonists on endometrial receptivity and implantation
by: Alberto Sola‐Leyva, et al.
Published: (2025-02-01)

The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and ratsResearch in context
by: Rune Ehrenreich Kuhre, et al.
Published: (2025-08-01)

Oral delivery of GLP-1 peptide using recombinant Lactobacillus gasseri for the treatment of type 2 diabetes mellitus
by: Zhiqiang Ke, et al.
Published: (2025-08-01)

Unlocking the potential of GLP-1 receptor agonists in ocular therapeutics: from molecular pathways to clinical impact
by: Zhixuan Xie, et al.
Published: (2025-07-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)